{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55","upperLimit":"80","value":"68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive oral lapatinib ditosylate once daily on days 1-21 and oral capecitabine twice daily on days 1-14.\n\nlapatinib ditosylate: Given orally\n\ncapecitabine: Given orally","id":"OG000","title":"Arm I"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"5 years","title":"Disease Control Rate","type":"SECONDARY","unitOfMeasure":"percentage"}